 to the phase three trials, so that would be Uganda and South Africa, but also that they will offer these as licenses to generic companies, which obviously is a great way to ensure that we do get this in an affordable way. Without this getting into the hands of young people, it obviously cannot work. Linda Galebecker, clearly thrilled.